News

EDITFORCE AND MITSUBISHI TANABE PHARMA ENTER INTO

LICENSE AGREEMENT

June 27, 2022

EditForce, Inc. (Headquarters: Fukuoka, President and CEO: Takashi Ono; hereinafter

“EditForce”) has entered into a License Agreement (hereinafter “Agreement”) with

Mitsubishi Tanabe Pharma Corporation (Headquarters: Osaka, Representative Director,

Hiroaki Ueno; hereinafter “MTPC”) to research, develop and commercialize potential gene

therapy products for a specific target disease in the field of CNS by utilizing EditForce’s

proprietary PPR protein platform technology.

In this alliance, MTPC and EditForce aim to create potential novel pharmaceuticals for the

specific CNS disease by utilizing the drug R&D know-how and global business experience

of MTPC and the novel biotechnology of EditForce. MTPC will acquire the exclusive right

to conduct the selection of drug candidate molecules, preclinical and clinical development,

manufacturing, and commercialization worldwide.

Under the terms of theAgreement, EditForce will receive an upfront payment and milestone

payments amounting to over ¥20 billion depending on the development stage and

commercialization progress, and royalties based on the worldwide sales after the launch.

“I am so delighted to reach the agreement with MTPC, which has an interest in our

proprietary PPR protein platform technology,” said Takashi Ono, President and CEO of

EditForce. “We look forward to working closely with MTPC to develop and deliver

breakthrough pharmaceutical products with our technology to patients suffering from

diseases.”

EditForce will proceed with R&D of pharmaceuticals using our PPR protein platform

technology.